These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 19730863
1. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Clyburn RD, Reid P, Evans CA, Lefley DV, Holen I. Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863 [Abstract] [Full Text] [Related]
2. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I. Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481 [Abstract] [Full Text] [Related]
3. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY. Lung Cancer; 2008 Feb 15; 59(2):180-91. PubMed ID: 17900752 [Abstract] [Full Text] [Related]
4. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. Br J Cancer; 2001 Apr 20; 84(8):1126-34. PubMed ID: 11308265 [Abstract] [Full Text] [Related]
5. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. Coxon JP, Oades GM, Kirby RS, Colston KW. BJU Int; 2004 Jul 20; 94(1):164-70. PubMed ID: 15217454 [Abstract] [Full Text] [Related]
6. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Clin Cancer Res; 2002 Nov 20; 8(11):3512-9. PubMed ID: 12429642 [Abstract] [Full Text] [Related]
8. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, Nilsson S. Acta Oncol; 2005 Jul 20; 44(6):644-50. PubMed ID: 16165924 [Abstract] [Full Text] [Related]
9. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I. Breast Cancer Res Treat; 2012 Jun 20; 133(2):523-36. PubMed ID: 21956211 [Abstract] [Full Text] [Related]
10. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies. Li L, Zhu Z, Joshi B, Porter AT, Tang DG. Anticancer Res; 1999 Jun 20; 19(1A):51-60. PubMed ID: 10226524 [Abstract] [Full Text] [Related]
11. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC. Acta Oncol; 2007 Jun 20; 46(5):669-77. PubMed ID: 17562444 [Abstract] [Full Text] [Related]
12. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, Uzunoglu S, Uslu R, Karaca B. BJU Int; 2012 Dec 20; 110(11 Pt C):E1147-54. PubMed ID: 22882676 [Abstract] [Full Text] [Related]
13. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ. Prostate; 2004 Mar 01; 58(4):382-93. PubMed ID: 14968439 [Abstract] [Full Text] [Related]
14. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Munshi A, McDonnell TJ, Meyn RE. Cancer Chemother Pharmacol; 2002 Jul 01; 50(1):46-52. PubMed ID: 12111111 [Abstract] [Full Text] [Related]
17. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD, Holen I. Cell Oncol (Dordr); 2013 Dec 01; 36(6):505-14. PubMed ID: 24177992 [Abstract] [Full Text] [Related]
18. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Int J Cancer; 2005 Jan 20; 113(3):364-71. PubMed ID: 15455384 [Abstract] [Full Text] [Related]
19. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Zhang X, Li W, Olumi AF. Clin Cancer Res; 2007 Dec 01; 13(23):7181-90. PubMed ID: 18056199 [Abstract] [Full Text] [Related]
20. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R. Clin Cancer Res; 2003 Jul 01; 9(7):2394-9. PubMed ID: 12855610 [Abstract] [Full Text] [Related] Page: [Next] [New Search]